Another dot or two that I think you may be interested in:
[DW - 23.7.24]: "The second thing is that we're open to are acquisitions and corporate activity, but only where it makes sense in that. And I've given the example before, but I think, you know, where it might make sense is if somebody had a sales force already, but in an area that we were not yet servicing. So, I mean, this is a crazy example, but it might be somebody says, I've got 100 people selling to every podiatrist in X country. And we say, well, we observed that it's being used in diabetic foot ulcers extensively. Well, maybe that sales force could be of use to us, and we just add our product into their kitbag." ~ https://aus biz.com.au/media/whats-fueling-this-small-caps-big-gain-?videoId=36930
Coincidentally, Avita has a salesforce of 108 people who will be promoting wound care products (a dermal scaffold is intended to be one of the products, and RECELL has FDA approval for ulcers) to existing burn accounts and an increasing number of trauma accounts in the US. However, I assume that PNV are already servicing these accounts effectively. If there's room for improvement, leveraging off a distributor that has 108 sales professionals with complementary products seems like a decent way to increase market penetration and revenue, without the expense and time associated with hiring new staff. Perhaps the following study is providing a little extra motivation (if not, it's at least something for PNV holders to keep an eye on):
This is a prospective, randomized, controlled, multi-center clinical study comparing SupraSDRM® to standard of care wound dressing, BTM, in the treatment of full-thickness wounds deemed not immediately suitable for definitive grafting will be performed.
AVH Price at posting:
$3.09 Sentiment: Buy Disclosure: Held
(20min delay)